Abstract 9749: In Vivo Results of Cobra Pzf ™ Stented Rabbit Iliac Arteries
Introduction: The CeloNova Cobra PzF™ coronary stent is a new stent design, balloon expandable cobalt chromium alloy that is pre-mounted on a custom rapid exchange balloon delivery catheter. The alloy stent is surface treated with a nano-layer Polyzene®-F (PzF). In vitro studies have indicated that the PzF surface treatment is a nonthrombogenic and has pro-endothelialization properties.
Methods: Only 3.0 mm diameter x 15 mm length stents were used, 32 external right iliac rabbit arteries were harvested at 7 days for electron microscopy analysis, half cylinder for thrombus area formation and the other half cylinder for reendothelialization. Then, a time course of reendothelialization was performed with 10 additional animals. Five animals were examined at day 3 and 5 animals at day 5. Each animal received in one leg a Cobra PzF stent and on the opposite leg a control stent randomly assigned. The 2 half cylinders were examined for reendothelialization.
Results: Thrombotic occlusion was a rare event in this experiment (3/52, 5.76%) of the stented vessels. The 3 occluded stents were observed in control Cobra BMS group (3/27, 11.11%) versus 0 (0/25, 0%) in the Cobra PzF™ group (p = 0.04). At day 7, almost a complete coverage of endothelial cells was observed in both group. 99.86 +/- 0.09 % in the Cobra BMS group versus 99.54 +/- 0.25% in the Cobra PzF™ group, (p = NS). The only defects of reendothelialization were observed on pieces of struts of stents in front of take off of large side branches in both group. No thrombus area was observed in both group at day 7, 0% versus 0%, (p = NS). At day 3, more than half area of the examined pieces was reendotheliazed in both group, 54.25 +/- 4.4 % in the Cobra PzF™ group versus 53.78 +/- 4.4 % in the Cobra BMS group (p = NS), and reached 78.30 +/- 3.7 % in the Cobra PzF™ group versus 79.03 +/- 4.% in the Cobra BMS group (p = NS). All stents were well expanded against the arterial wall and no struts were malapposed with no difference between groups.
Conclusions: There is a significant reduction of stent occlusion in the Cobra PzF™ group as compared to the same stent without PzF modified surface, with a complete and rapid reendothelialization in both group at day 7 that proves the benefit both of this new thin struts deign and the modified PzF surface.
Author Disclosures: L. Maillard: Consultant/Advisory Board; Modest; Celonova. D. Corseaux: None. A. Altié: None. A. Ung: None. J. Courageot: None. E. Teiger: None. E. Van Belle: None.
- © 2014 by American Heart Association, Inc.